Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Abstract

Background MicroRNAs (miRNAs) have been found to play an important role in the development and outcomes for multiple human cancers. Their role as a prognostic biomarker in non-small-cell lung cancer (NSCLC) remains unclear. This meta-analysis aims to clarify the role of various miRNAs in the survival of NSCLC patients. Materials and Methods All studies were identified through medical database search engines. A meta-analysis was conducted to assess the correlation between miRNAs expressions and overall survival among those NSCLC studies. Relevant data were extracted from each eligible study regarding baseline characteristics and key statistics such as hazard ratio (HR), 95% confidence interval (CI), and P value, which were utilized to calculate a pooled effect size. Result Thirty-two studies were included in the meta-analysis. Using a random effect model, the combined HR and 95% CI for overall survival (OS) was calculated as 1.59 (1.39–1.82), predicting a poor overall survival. Five miRNAs (miR-21, miR-155, miR-let-7, miR-148a, and miR-148b) were found to be of significance for predicting OS in at least two studies, hence, selected for subgroup analysis. Subgroup analysis disclosed that elevated levels of miR-21 and miR-155 in both cancer tissue and blood samples were associated with worse OS. Compared to American studies (I-squared: <0.001% and P value: 0.94), Asian and European studies exhibited greater heterogeneity in miRNA expression and relationship to OS (I-squared, P values were approximately 78.85%, <0.001 and 61.28%, 0.006, respectively). These subgroup analyses also highlighted that elevated expression of miR-21 and miR-155 and low levels of expression of miR-148a, miR-148b, and miR-let-7 were associated with poor prognosis in NSCLC. Conclusion miR-21, miR-155, miR-148a, miR-148b, and miR-let-7 are consistently up- or downregulated in NSCLC and are associated with poor OS. These miRNAs show potential as useful prognostic biomarkers in the diagnosis, treatment, and follow-up of NSCLC.

The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

“…It can even play a role in the patient's lifelong disease surveillance and is of great help to clinical thearapy. This meta-analysis found that miR-155 has no obvious prognostic effect on lung cancer, which is inconsistent with results of some previous prognostic studies, while the result is consistent with the prognostic value of miR-155 of NSCLC reported in a meta-analysis published by Lamichhane SR et al in 2018 [43]. However, the sample size included in our meta-analysis is larger than previous mata-analysis, more researches with sufficient data will be needed to verify this result.…”

The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

“…It can even play a role in the patient's life-long disease surveillance and is of great help to clinical thearapy. This meta-analysis found that miR-155 has no obvious prognostic effect on lung cancer, which is inconsistent with results of some previous prognostic studies, while the result is consistent with the prognostic value of miR-155 of NSCLC reported in a meta-analysis published by Lamichhane SR et al in 2018 [43]. However, the sample size included in our meta-analysis is larger than previous mata-analysis, more researches with sufficient data will be needed to verify this result.…”

Downregulated microRNA‑140‑5p expression regulates apoptosis, migration and invasion of lung cancer cells by targeting zinc finger protein 800

“…A number of miRNAs play significant roles in the pathophysiology of different types of cancer, including lung cancer (39,40). Based on previous studies, let-7, miR-126, miR-598, miR-148a/b and miR-7 are known to be dysregulated in lung cancer (41)(42)(43)(44). To the best of our knowledge, the present study was the first to demonstrate that miR-140-5p exhibits anticancer functions in lung cancer by regulating ZNF800.…”